Twist Bioscience (NASDAQ:TWST) Stock Price Down 4.4%

Twist Bioscience Co. (NASDAQ:TWST)’s stock price fell 4.4% during mid-day trading on Tuesday . The stock traded as low as $27.90 and last traded at $27.95. 98,884 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 907,806 shares. The stock had previously closed at $29.24.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Scotiabank increased their target price on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 5th. The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and increased their target price for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Finally, Barclays lowered their target price on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 10th.

Twist Bioscience Trading Down 0.1 %

The company has a fifty day moving average of $35.85 and a two-hundred day moving average of $29.94.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.03. The business had revenue of $71.50 million during the quarter, compared to analyst estimates of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. Twist Bioscience’s revenue for the quarter was up 31.8% compared to the same quarter last year. During the same period last year, the company earned ($0.74) EPS. Research analysts forecast that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In related news, Director Robert Chess sold 4,110 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the completion of the sale, the director now directly owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of Twist Bioscience stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $34.98, for a total transaction of $143,767.80. Following the completion of the transaction, the director now owns 64,169 shares in the company, valued at approximately $2,244,631.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,128 shares of Twist Bioscience stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total value of $37,810.56. Following the transaction, the chief executive officer now owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,037 shares of company stock valued at $384,092. Corporate insiders own 3.92% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its stake in shares of Twist Bioscience by 3.3% in the 3rd quarter. Royal Bank of Canada now owns 9,025 shares of the company’s stock worth $318,000 after buying an additional 291 shares during the last quarter. Captrust Financial Advisors lifted its stake in Twist Bioscience by 101.3% in the second quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock valued at $27,000 after purchasing an additional 382 shares during the last quarter. D.A. Davidson & CO. grew its holdings in Twist Bioscience by 3.4% during the fourth quarter. D.A. Davidson & CO. now owns 16,774 shares of the company’s stock valued at $618,000 after purchasing an additional 554 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Twist Bioscience by 16.0% during the first quarter. Ameritas Investment Partners Inc. now owns 4,293 shares of the company’s stock valued at $212,000 after purchasing an additional 591 shares during the period. Finally, US Bancorp DE grew its holdings in Twist Bioscience by 11.8% during the first quarter. US Bancorp DE now owns 5,942 shares of the company’s stock valued at $295,000 after purchasing an additional 626 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.